In summary, our study identifies PTN as a metastasis-associated factor that can facilitate local immune suppression favoring cancer cell colonization at secondary sites and therefore presents a novel therapeutic target in the treatment of metastatic TNBC. The gene discussed is PTN; the disease is cancer.